Conference call to discuss positive initial Phase 1 clinical data today at 8:30 a.m. ETCAMBRIDGE, Mass., Jan. 10, 2025 (GLOBE ...

Mersana Therapeutics Inc. (NASDAQ:MRSN) released initial data from the Phase 1 dose escalation and backfill cohorts for ...

Mersana Therapeutics (MRSN) announced positive initial clinical data from the Phase 1 dose escalation and backfill cohorts for emiltatug ...

Mersana Therapeutics (MRSN) stock hits a 52-week low in reaction to early clinical results for its cancer drug Emi-Le in ...

Analyst Charles Zhu from LifeSci Capital maintained a Buy rating on Mersana Therapeutics (MRSN – Research Report) and keeping the price target ...

Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug ...

Mersana on Friday said the new designation covers the drug, XMT-1660, for the treatment of advanced or metastatic breast cancer in patients with human epidermal growth factor receptor 2 low or ...

Announces Positive Initial Clinical Data for Emi-Le in Cancer Treatment ...

Why Teledyne Technologies Shares Are Trading Lower By 9%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session Avi Kapoor Why Butterfly Network Shares Are Trading Lower By 22%? Here Are ...

Orphan Drug Tag For Mersana's Gastric Cancer Candidate Vandana Singh Mersana Therapeutics Director Andrew Hack Reported Purchase of 350,000 Shares @ Avg Price of $3.25/Share in Form 4 Filing on ...

PacBio (NASDAQ: PACB), developer of the world's most advanced sequencing technologies, and Intus Bio, a leader in microbiome ...

Mercedes-Benz experienced a decline in core car sales throughout 2024, reflecting a challenging year for the auto industry, ...